The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $23.67 in the prior trading day, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $22.53, down -4.82%. In other words, the price has decreased by -$4.82 from its previous closing price. On the day, 1.14 million shares were traded. ARWR stock price reached its highest trading level at $23.92 during the session, while it also had its lowest trading level at $22.47.
Ratios:
Our goal is to gain a better understanding of ARWR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 2.45 whereas as Long-Term Debt/Eq ratio is at 2.42.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 04, 2023, initiated with a Buy rating and assigned the stock a target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Hamilton James C sold 6,000 shares for $28.03 per share. The transaction valued at 168,180 led to the insider holds 204,851 shares of the business.
Lu Hongbo bought 1,000 shares of ARWR for $27,500 on Mar 20 ’24. The Director now owns 33,680 shares after completing the transaction at $27.50 per share. On Mar 19 ’24, another insider, Lu Hongbo, who serves as the Director of the company, bought 1,000 shares for $28.00 each. As a result, the insider paid 28,000 and bolstered with 32,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2791399424 and an Enterprise Value of 2983595520. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.36 while its Price-to-Book (P/B) ratio in mrq is 15.10. Its current Enterprise Value per Revenue stands at 16.417 whereas that against EBITDA is -10.456.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $42.48, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is -23.34%, while the 200-Day Moving Average is calculated to be -23.60%.
Shares Statistics:
The stock has traded on average 1.27M shares per day over the past 3-months and 831840 shares per day over the last 10 days, according to various share statistics. A total of 123.90M shares are outstanding, with a floating share count of 117.63M. Insiders hold about 5.06% of the company’s shares, while institutions hold 64.23% stake in the company. Shares short for ARWR as of 1711584000 were 8868758 with a Short Ratio of 6.99, compared to 1709164800 on 8838910. Therefore, it implies a Short% of Shares Outstanding of 8868758 and a Short% of Float of 8.4.
Earnings Estimates
Arrowhead Pharmaceuticals Inc. (ARWR) is currently under the scrutiny of Arrowhead Pharmaceuticals, Inc. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $17.51, with high estimates of $28.49 and low estimates of $67.15.
